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Objectives The study sought to evaluate the ability of cardiac magnetic resonance (CMR) to monitor acute and long-term 
changes in pulmonary vascular resistance (PVR) noninvasively. 
Background PVR monitoring during the follow-up of patients with pulmonary hypertension (PH) and the response to vasodilator 
testing require invasive right heart catheterization. 
Methods An experimental study in pigs was designed to evaluate the ability of CMR to monitor: 1) an acute increase in PVR 
generated by acute pulmonary embolization (n = 10); 2) serial changes in PVR in chronic PH (n = 22); and 3) 
changes in PVR during vasodilator testing in chronic PH (n = 10). CMR studies were performed with simultaneous 
hemodynamic assessment using a CMR-compatible Swan-Ganz catheter. Average flow velocity in the main 
pulmonary artery (PA) was quantified with phase contrast imaging. Pearson correlation and mixed model analysis 
were used to correlate changes in PVR with changes in CMR-quantified PA velocity. Additionally, PVR was estimated 
from CMR data (PA velocity and right ventricular ejection fraction) using a formula previously validated. 
Results Changes in PA velocity strongly and inversely correlated with acute increases in PVR induced by pulmonary embolization 
(r = -0.92), serial PVR fluctuations in chronic PH (r = -0.89), and acute reductions during vasodilator testing (r = -0.89, 
p < 0.01 for all). CMR-estimated PVR showed adequate agreement with invasive PVR (mean bias -1.1 Wood units,; 95% 
confidence interval: -5.9 to 3.7) and changes in both indices correlated strongly (r = 0.86, p < 0.01). 
Conclusions CMR allows for noninvasive monitoring of acute and chronic changes in PVR in PH. This capability may be valuable 
in the evaluation and follow-up of patients with PH. (J Am Coll Cardiol 2013;62:1621-31) © 2013 by the 
American College of Cardiology Foundation 
Abbreviations 
and Acronyms 
CMR = cardiac magnetic 
resonance 
PA = pulmonary artery 
PCWP = pulmonary capillary 
wedge pressure 
PH = pulmonary 
hypertension 
PVR = pulmonary vascular 
resistance 
RHC = right heart 
catheterization 
RV = right ventricular 
WU = Wood units 
Pulmonary vascular resistance 
(PVR) has important implications 
for the management and prognosis 
in patients with pulmonary hy-
pertension (PH) (1) and chronic 
heart failure (2). Moreover, mean 
pulmonary artery (PA) pressure, 
and/or PVR response during acute 
vasodilator testing correlates with 
prognosis (3-5) and helps guiding 
physicians with the selection of 
appropriate therapy (1,6,7). 
Currently, both acute vasodi-
lator testing and PVR monitoring 
require invasive right heart cath-
eterization (RHC). An accurate 
noninvasive alternative would be helpful to eliminate the 
discomfort, radiation exposure, and small but real risk of 
morbidity and mortality associated with R H C (8). Doppler 
echocardiography has become routine in the follow-up of 
patients with P H due to its ability to estimate systolic PA 
pressure, but has limited accuracy (9) and applicability (i.e., 
poor acoustic window or absence of tricuspid regurgitation) 
and it is not widely accepted for PVR estimation (10). 
Cardiac magnetic resonance (CMR) has been proposed as an 
alternative in assessing pulmonary hemodynamics non-
invasively (11-15). It has been previously demonstrated that 
average PA flow velocity correlates strongly with PVR, and 
that C M R allows for noninvasive estimation of PVR values 
(16). However, whether CMR can accurately monitor serial 
changes in PVR is unknown. Therefore, our aim was to 
determine the ability of C M R to track acute and chronic 
fluctuations in PVR from serial changes in average PA 
velocity and CMR-estimated PVR. 
Methods 
Study design and experimental models. Experimental 
procedures were performed in castrated male Large-White 
pigs. The study was approved by the Institutional Animal 
Research Committee and carried out in compliance with the 
Guide for the Care and Use of Laboratory Animals. Before 
any procedure, anesthesia was induced by intramuscular 
injection of ketamine (20 mg/kg), xylazine (2 mg/kg), and 
midazolam (0.5 mg/kg), with buprenorphine (0.3 mg/kg) 
for analgesia, and the animals were intubated. All C M R and 
hemodynamic measures were obtained during spontaneous 
ventilation, anesthesia maintained with intravenous mida-
zolam (0.2 mg/kg/h), and continuous electrocardiographic 
and oxymetric monitoring. 
The ability of C M R to detect changes in PVR was 
evaluated under 3 different conditions: 
1. Acute P H (n = 10), generated inside the mag-
net by pulmonary embolization with polydextrane-
microspheres with a diameter of 300 |lm (Sephadex 
G50, Pharmacia Biotech GmbH, Freiburg, Germany) 
(17) through the femoral vein. Each animal received 
a different dose from a suspension with 2.5 mg of 
microspheres per milliliter of saline (between 100 and 
400 mg, median of 200 mg) in order to achieve a wide 
range of acute P H severity. C M R imaging with 
simultaneous hemodynamic monitoring was per-
formed immediately pre- and post-embolization. 
2. Chronic P H (n = 22), using 2 different models. 
Pre-capillary P H (n = 9) was generated with repeated 
microsphere embolization in a variant of a model previ-
ously described (18), using similar methodology as em-
ployed in the acute model but during mechanical 
ventilation. The first pulmonary embolization was per-
formed in 3-month-old pigs (weight = 4 0 kg) and 
repeated weekly until chronic stable P H was generated 
(mean PA pressure >25 mm Hg at rest). A median of 4 
embolizations (range 3 to 6) with a median dose 
of microspheres of 500 mg was required to induce 
sustained P H . 
Post-capillary P H (n = 13) was generated by 
surgical nonrestrictive banding of the main pulmonary 
vein (venous confluent arising from the junction of 
both inferior pulmonary veins) through a small 
thoracotomy in 4-week-old piglets (weight ~ 10 kg), 
a variant of a model previously described (19). This 
venous confluent drains both inferior pulmonary 
lobes, which account for ~ 80% of total lung mass 
(Figs. 1A and IB). Restriction of flow and secondary 
P H arise progressively as the animal grows. Animals 
were maintained with inhaled sevofluorane (1.5% to 
2.0%) during the procedure under mechanical venti-
lation. The external jugular vein and internal carotid 
artery were dissected and cannulated for continuous 
recording of systemic and PA pressures. There was no 
perioperative mortality but 2 animals died suddenly 
during the follow-up period (2 and 3 months after the 
operation).CMR studies with simultaneous hemody-
namic monitoring were performed at baseline, once 
chronic P H was generated, and every 4 weeks there-
after for 2 and 4 months, in the pre- and post-capillary 
models, respectively. 
3. Acute vasodilator testing (n = 10 animals with chronic 
PH; 5 with pre- and 5 with post-capillary PH) was 
performed inside the magnet by increasing the inhaled 
oxygen concentration to 100% with all other conditions 
in steady state. C M R imaging with simultaneous 
hemodynamic monitoring was performed immediately 
before and 5 min after oxygen administration. 
Invasive hemodynamic assessment. Hemodynamic measure-
ments, obtained using a Swan-Ganz catheter via femoral or 
internal jugular vein, included mean PA pressure, pulmonary 
capillary wedge pressure (PCWP) at end-expiration, and cardiac 
output assessed by thermodilution. PVR was calculated as the 
difference between mean PA pressure and the estimated left 
atrial pressure divided by the cardiac output in Wood units 
Selective Nonrestrictive Banding of the Venous Confluent Draining Both Inferior Pulmonary Lobes 
(A) Diagram shows the anatomy of the pulmonary venous circulation and Its drainage pattern Into the left atrium In pigs. The Inferior venous confluent has been encircled. 
(B) Surgical photograph showing the banding of the venous confluent at the exact resting diameter. 
(WU). In animals with pre-capillary PH, PCWP was used as an 
estimate of left atrial pressure (mean difference between PCWP 
and left ventricular end-diastolic pressure of 0.8 mm Hg in 
a pilot study, N = 12), whereas in animals with post-capillary 
PH, left ventricular end-diastolic pressure quantified with 
a pigtail catheter was used, due to the variation of PCWP 
measurements amongst pulmonary lobes. Cardiac output and 
PVR were also indexed by body surface area estimated by the 
Brody's formula (20). Immediately after RHC, the Swan-Ganz 
catheter was replaced for a CMR-compatible version (Edwards, 
Irvine, California) and the animal was transferred to the CMR 
suite, adjacent to the catheterization laboratory. 
CMR studies, CMR ACQUISITION. All C M R studies were 
performed with a 3.0-T magnet (Achieva-Tx, Philips Me-
dical Systems, Best, the Netherlands), equipped with a 32-
channel cardiac phased-array surface coil and retrospective 
electrocardiographic gating. Images were obtained with 
simultaneous monitoring of PA and systemic pressures using 
a CMR-compatible monitor (Invivo, Orlando, Florida). 
Steady-state free precession cine sequences were acquired in 
10 to 15 contiguous short axis slices covering both ventricles 
from base to apex, and reconstructed into 25 cardiac phases 
each for the evaluation of ventricular volumes and function. 
Two-dimensional flow imaging (phase-contrast) was per-
formed perpendicular to the main PA with a velocity-encoded 
gradient echo sequence using the minimum upper velocity 
limit without signal aliasing. For this purpose, 2 double-
oblique orthogonal views oriented along the main axis of the 
PA trunk were acquired with a standard steady-state free 
precession cine sequence and used as the reference to prescribe 
a plane perpendicular to the main PA for the acquisition of 
phase-contrast images (Fig. 2). Similarly, 2D flow imaging in 
a cross-sectional view of the ascending aorta was obtained 
to determine left cardiac output. The following imaging 
parameters were applied for 2D flow imaging: repetition time/ 
echo time 5.4/3.4 ms; number of averages 2; slice thickness 8 
mm; voxel size 2.5 x 2.5 mm; reconstructed heart phases 40. 
In chronic P H animals, 2D flow imaging was performed at 
each visit. The agreement between cardiac output obtained 
by aortic 2D flow imaging and thermodilution was excellent 
(0.1 ± 0.4 1/min; R = 0.92, p < 0.01). Thus, in the acute 
models, where thermodilution could not be performed inside 
the magnet, cardiac output as assessed by phase-contrast of the 
aorta was used to compute PVR immediately before and after 
the intervention. In animals with chronic PH, 3D flow 
imaging on the main PA was additionally acquired. 
CMR ANALYSIS. Short-axis steady-state cine and 2D phase-
contrast acquisitions were analyzed using specialized soft-
ware (Extended M R Workspace, Philips Medical Systems). 
Observers were blinded to the study arm and hemodyna-
mic measurements. On cine images, biventricular endocardial 
contours were manually traced in end-diastole and end-systole 
and Simpson's method was used to calculate volumes and 
ejection fraction. Right ventricular (RV) trabeculations were 
included within the blood pool. Similarly, the inner contours 
of the main PA and aorta cross sections were outlined in each 
cardiac phase to quantify the average velocity during the 
complete cardiac cycle, minimum and maximum areas, and 
cardiac output. No phase-offset correction was performed, as 
the bias was negligible (data not shown). In a pilot study, we 
confirmed that the presence of the Swan-Ganz catheter inside 
the PA did not cause significant error in the estimation of 
average PA flow velocity (intraclass correlation coefficient of 
0.95 and mean bias of 0.2 cm/s). PA elasticity was calcula-
ted as: (maximal area - minimal area)/minimal area x 100. 
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Phase Contrast Imaging of the Main PA 
(A, B) Double-oblique orthogonal views oriented along the main axis (yellow line) of the pulmonary arterial (PA) trunk acquired with a steady-state free precession cine 
sequence. (C, D) Phase-contrast Imaging on the main PA ([C] anatomic view, [D] flow-encoded view). White arrow in C represents Swan-Ganz catheter Inside the 
pulmonary artery encircled In red. 
CMR-estimated PVR was calculated using the formula 
previously validated (16) as: PVR (WU) = 19.38 - [4.62 x 
In PA velocity (cm/s)] - [0.08 x RV ejection fraction (%)]. 
3D-phase-contrast acquisitions were analyzed using GTFlow 
package (Gyrotools Inc., Zurich, Switzerland). PA was 
segmented semiautomatically using morphological operators 
and blood flow pathlines were generated for the qualitative 
assessment of flow patterns and detection of vortices (21). 
Histopathology. At the completion of the study, animals 
with chronic P H were euthanized with a lethal injection of 
pentobarbital sodium and the heart, PA, and lung parenchyma 
were excised. Macroscopic high-resolution photographs were 
taken using a digital camera. Standard hematoxylin and eosin 
staining, and picrosirius red and Masson's trichrome staining 
were performed to evaluate microscopic changes and the 
presence of collagen in order to demonstrate typical lesions 
in the chronic P H models. A stereomicroscope Nikon SMZ 
1500 (Nikon Instruments Inc., Melville, New York) was used. 
Statistical analysis. Continuous variables are expressed as 
median (interquartile range or range). For the evaluation of 
serial changes in PVR (second condition), average PA 
velocity was natural logarithm-transformed because its 
association with PVR in chronic P H is curvilinear, as pre-
viously described (16). Correlation between acute changes in 
PA velocity and PVR induced by pulmonary embolization or 
vasodilator testing was assessed using Pearson correlation. 
Mixed model analysis with correction for repeated mea-
surements was used to correlate changes in PVR and changes 
in PA velocity in chronic PH, and to develop an equation to 
predict the change in PVR per percent change in PA velocity. 
Changes in PVR and PA velocity in chronic P H were 
calculated as the difference between measurements in 2 
consecutive follow-up visits. Changes in PA velocity and 
PVR were further dichotomized to assess sensitivity, speci-
ficity, and positive and negative predictive values of a reduc-
tion of PA velocity to detect an increase in PVR. Analyses 
were performed using STATA version 12 (StataCorp LP, 
College Station, Texas) and SPSS version 20 (IBM Corp., 
Armonk, New York). 
Results 
Ability of CMR to track changes in PVR. ACUTE PH. Acute 
pulmonary embolization caused an increase in PVR (median 
1 Changes in 
Heart rate, beats/min 
Oxygen saturation, % 
Mean BP, mm Hg 
Mean PA pressure, mm Hg 
Cardiac output, l/min 
PCWP, mm Hg 
PVR, Wood units 
PA flow velocity, cm/s 
PA minimal area, cm2 
PA elasticity, % 
Hemodynamic and Phase Contrast Parameters During Acute Embolization 
Baseline 
76.0 (14.0) 
97.5 (5.0) 
92.0 (26.0) 
18.0 (10.0) 
3.7 (1.7) 
11.5 (3.0) 
1.8 (2.2) 
13.5 (6.5) 
3.6 (1.3) 
28.6 (24.5) 
Post-Embolization 
80.5 (24.0) 
94.5 (16.0) 
85.5 (33.25) 
37.5 (12.0) 
2.7 (1.3) 
11.5 (4.3) 
10.0 (4.9) 
8.5 (3.9) 
5.6 (2.8) 
15.1 (11.4) 
Change 
2.0 ( -14 to 27) 
- 3 .5 ( -24 to 6) 
- 6 .5 ( -43 to 7) 
17.5 (5.0 to 32.0) 
-0 .7 (-2.7 to 0.5) 
0 (-1 to -1) 
6.8 (1.4 to 11.7) 
4.9 (0.1 to 11.0) 
1.6 (0.2 to 3.8) 
- 9 . 6 ( - 38 to 7) 
p Value 
0.39 
0.12 
0.07 
<0.01 
0.02 
1.00 
<0.01 
<0.01 
<0.01 
0.04 
Values at baseline and post-embolization are median (interquartile range) and change is expressed as median (minimum to maximum). 
BP = blood pressure; IQR = interquartile range; PA = pulmonary artery; PCWP = pulmonany capillary wedge pressure; PVR = pulmonaty vascular 
resistance. 
6.8 WU; range 1.4 to 11.7 WU) and mean PA pressure 
(median 17.5 mm Hg; range 5 to 32 mm Hg) with a 
reduction in cardiac output (median 0.7 l/min; range 0 to 2.7 
l/min). These hemodynamic changes were accompanied by 
a significant decrease in PA velocity, an increase in PA area, 
and a reduction in PA elasticity (Table 1). 
The magnitude of the fall in PA velocity strongly corre-
lated with the increment in PVR (r = -0.92, p < 0.001) 
(Fig. 3A). The change in PVR moderately correlated with 
the change in PA elasticity (r = -0.63, p = 0.05) and did not 
correlate with the change in PA area (r = 0.30, p = 0.39). 
CHRONIC PH. Baseline and follow-up characteristics of the 
chronic P H animals are shown in Tables 2 and 3. 
An increase in cardiac output along the follow-up related 
with animal growth was observed in both models. Changes in 
PVR between follow-up visits were greater in the post-
capillary model compared to the pre-capillary model (median 
0.5 W U [range -5.4 to 19.0 WU] vs. median 0.1 W U [range 
-2.5 to 2.6 WU] , respectively, p = 0.08). 
Serial changes in between-visits PA velocity by C M R 
strongly correlated with changes in PVR (r = -0.89, p < 0.01) 
(Fig. 3B). According to the equation obtained: change in 
PVR (WU) = -0.2 - 11.2 x change in ln[PA velocity 
(cm/s)], it can be estimated that average PVR increased 
approximately 1 W U for each 10% decrease in PA velocity. 
Subgroup analysis showed better correlation in the post-
capillary than the pre-capillary model (r = -0.92, p < 0.01 
vs. r = -0.76, p < 0.01; p value for the interaction <0.01). 
Figure 4 shows some examples of the evolution of PVR and 
PA velocity during follow-up. Sensitivity, specificity, positive 
predictive value, and negative predictive values for a reduction 
in PA velocity to detect an increase in PVR were 86%, 
70%, 79%, and 79%, respectively. Serial changes in between-
visits PVR moderately correlated with changes in PA area 
(r = 0.61, p < 0.01) and changes in PA elasticity (r = -0.50, 
p < 0.01). Serial changes in between-visits PA velocity by 
C M R also correlated well with changes in indexed PVR 
(r = -0.82, p < 0.01). Animal weight and heart rate did not 
behave as confounders on the association between changes in 
PA velocity and PVR. 
The concordance between absolute values of invasive PVR 
and CMR-estimated PVR during follow-up using the 
previously published formula (that includes average PA 
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the 3 Different Conditions 
monary artery; PVR = pulmonary vascular resistance; 
1 Baseline and Follow-Up Characteristics of Chronic Pre-Capillary PH Group 
Weight, kg 
Body surface area, m2 
Heart rate, beats/min 
Oxygen saturation, % 
Mean BP, mm Hg 
Mean PA pressure, mm Hg 
Cardiac output, l/min 
Cardiac index, l /min/m2 
PCWP, mm Hg 
PVR, Wood units 
PVR index, Wood units»m2 
Average PA velocity, cm/s 
PA minimal area, cm2 
PA elasticity, % 
Baseline 
40.0 (15.0) 
1.0 (0.23) 
75.0 (8.0) 
94.0 (6.0) 
97.0 (9.0) 
21.0 (9.0) 
4.3 (1.0) 
4.1 (0.6) 
9.0 (1.0) 
2.3 (1.4) 
2.9 (1.8) 
11.0 (2.8) 
5.4 (2.1) 
32.3 (10.7) 
At Generation 
55.0 (16.0) 
1.2 (0.2) 
75.0 (16.0) 
90.0 (2.0) 
95.0 (16.0) 
28.0 (3.0) 
6.2 (1.1) 
4.6 (0.7) 
12.0 (5.0) 
2.7 (1.3) 
3.1 (1.6) 
11.6 (2.5) 
6.3 (0.7) 
36.9 (5.1) 
Chronic PH 
After 1 Month 
68.5 (4.0) 
1.4 (0.1) 
70.0 (10.0) 
94.0 (3.0) 
97.0 (9.0) 
27.0 (5.0) 
6.0 (1.6) 
4.3 (0.8) 
10.0 (4.0) 
2.7 (2.2) 
3.4 (0.7) 
11.7 (3.2) 
7.2 (1.0) 
37.7 (6.2) 
After 2 Months 
81.0 (4.0) 
1.6 (0.05) 
74.0 (13.0) 
92.0 (3.0) 
103 (9.0) 
27.0 (3.0) 
7.2 (1.4) 
4.6 (0.5) 
13.0 (8.0) 
2.2 (1.1) 
3.2 (1.5) 
10.9 (1.8) 
8.0 (1.4) 
30.0 (7.1) 
Values are median (interquartile range). 
PH = pulmonary hypertension; other abbreviations as in Table 1 . 
velocity and RV ejection fraction) (16) was adequate 
(r = 0.83, p < 0.01; mean bias o f - 1 . 1 W U and limits of 
agreement o f -5 .9 and 3.7 WU). Serial changes in CMR-
estimated PVR and changes in invasive PVR showed 
a good concordance as well (r = 0.86, p < 0.01; mean bias of 
-0.14 W U and limits of agreement of -4.7 and 4.4 WU), 
although a trend to underestimate large PVR changes was 
observed (Fig. 5). 
In addition to changes in quantitative parameters, the 
appearance of vortices in the flow of the main PA could be 
identified with 3D phase-contrast imaging in all animals 
with chronic P H (Fig. 6, Online Videos 1 and 2). 
ACUTE VASODILATOR TESTING. Oxygen administration 
caused a reduction in PVR (median -2 .1 WU, range -3.8 to 
0.2 WU) and mean PA pressure (median -7.0 mm Hg, 
range -15 to 1 mm Hg), without significant changes in 
cardiac output (median 0.0 1/m, range -0.8 to 0.5 l/min). 
These hemodynamic changes were accompanied by a 
significant increase in PA velocity, an increase in PA elas-
ticity, and a reduction in PA area (Table 4). 
The change in PA velocity strongly correlated with the 
reduction in PVR (r = -0.89, p = 0.01) (Fig. 3C) and mean 
PA pressure (r = -0.86, p = 0.02). Baseline PA elasticity 
(before vasodilator testing) significantly correlated with the 
change in PVR (r = 0.73, p = 0.04) but the acute change in 
PVR did not correlate with the acute change in PA area or 
elasticity. 
Histopathologic examination. Chronic P H generation 
was associated in both experimental models with typical 
changes of arterial intimal proliferation, hypertrophy of the 
media and perivascular fibrosis of vessels inside the lung, 
hypertrophy and increased collagen deposition in the media 
1 Baseline and Follow-Up Characteristics of Chronic Post-Capillary PH Group 
Weight, kg 
BSA, m2 
Heart rate, beats/min 
Oxygen saturation, % 
Mean BP, mm Hg 
Mean PA pressure, mm Hg 
Cardiac output, l/min 
Cardiac index, l /min/m2 
LVEDP, mm Hg 
PVR, Wood units 
PVR index, Wood units»m2 
Average PA velocity, cm/s 
PA minimal area, cm2 
PA elasticity, % 
Baseline 
12.5 (2.0) 
0.5 (0.05) 
120.0 (21.0) 
99.0 (1.0) 
57.0 (8.0) 
19.0 (3.0) 
1.9 (0.6) 
3.6 (0.8) 
14.0 (2.0)* 
2.5 (1.4) 
1.0 (0.6) 
14.7 (1.9) 
1.8 (0.3) 
42.9 (12.1) 
1 Month 
22.5 (3.0) 
0.7 (0.06) 
98.0 (18.0) 
90.0 (11.0) 
77.0 (15.0) 
30.0 (10.0) 
3.3 (0.8) 
4.8 (1.1) 
6.0 (3.0) 
6.7 (1.5) 
4.2 (1.1) 
11.0 (3.0) 
3.7 (1.2) 
21.2 (10.8) 
2 Months 
40.0 (10.5) 
1.0 (0.2) 
74.0 (14.0) 
91.0 (6.0) 
92.5 (17.5) 
36.0 (14.0) 
4.4 (1.4) 
4.3 (1.0) 
8.0 (2.0) 
7.1 (4.6) 
6.4 (5.2) 
11.0 (2.9) 
5.4 (2.1) 
32.5 (8.3) 
3 Months 
57.3 (11.0) 
1.3 (0.1) 
68.0 (9.5) 
93.0 (4.0) 
93.5 (12.5) 
34.5 (14.0) 
5.9 (1.0) 
4.3 (0.7) 
9.0 (3.5) 
4.0 (2.1) 
5.8 (3.2) 
11.4 (1.8) 
6.3 (1.9) 
35.2 (19.0) 
4 Months 
80.5 (5.5) 
1.6 (0.1) 
62.0 (11.0) 
95.0 (3.0) 
91.0 (7.0) 
35.0 (8.0) 
6.8 (2.7) 
4.3 (1.1) 
9.0 (4.0) 
3.7 (1.0) 
6.2 (2.2) 
11.5 (2.9) 
7.8 (1.3) 
31.6 (21.2) 
Values are median (interquartile rani 
BSA = body surface area; LVEDP 
¡e). *Pulmonary wedj 
= left ventricular end-
*e pressure at end-expiration was used instead of EDLVP at baseline, 
•diastolic pressure; other abbreviations as in Tables 1 and 2. 
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of the main PA, and RV dilatation, hypertrophy and 
myocardial fibrosis and disarray (Fig. 7). 
Discussion 
The main findings of this study are the following: 1) C M R 
allows noninvasive monitoring of serial changes in PVR in 
chronic PH; 2) semiquantitative monitoring can be per-
formed by determining simple changes in average PA flow 
velocity; and 3) variations in average PA velocity additionally 
have the ability to track acute increases or decreases in PVR. 
PVR monitoring by R H C is recommended in patients with 
chronic P H and those with heart failure awaiting heart 
transplantation (2). It has been recently reported that 
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Diagnostic Accuracy of the CMR Formula to Monitor Changes in PVR 
Correlation (A) and Bland-Altman plot (B) showing the association between changes in PVR as assessed by right heart catheterization (invasive PVR) and changes in PVR 
estimated based on cardiac magnetic resonance (CMR) data (CMR-quantified PVR). Abbreviations as in Figure 3. 
Three-Dimensional Phase Contrast Imaging of the Main Pulmonary Artery 
(A) Control animal without pulmonary hypertension showing laminar flow. (B) Case of post-capillary pulmonary hypertension showing turbulent flow and formation of a flow vortex 
in the main pulmonary artery (arrow). Please see Online Videos 1 and 2. 
a method combining the average PA velocity and RV ejection 
fraction, both measured by CMR, allowed noninvasive esti-
mation of PVR in patients with chronic P H at a single time 
point (16). In the present study we further evaluated whether 
this approach would be able to monitor serial changes in PVR, 
and therefore its potential for noninvasive follow-up, in 
experimental models of chronic PH. The 2 models employed 
led to the expected abnormalities not only in hemodynamics 
but also in cardiovascular adaptation to chronic pressure 
overload, as confirmed by the changes in the heart and 
pulmonary artery demonstrated in histopathological analyses 
(Fig. 7). Overall, PVR tended to increase initially and stabilize 
during follow-up. However, some subjects showed reduction 
of PVR between visits due to adaptation mechanisms, which 
allowed us to evaluate the accuracy of C M R to track changes in 
PVR on both directions. This mimics clinical PH, with 
between-visits PVR increase due to disease progression or 
reduction with treatment. W e were able to replicate the 
accuracy of the previously reported C M R method (16) in this 
experimental setting again with narrower limits of agreement 
than those reported with echocardiography (10,22,23) and, 
most importantly, demonstrate its ability to track variations in 
PVR over time. 
The combination of RV ejection fraction and average PA 
velocity enables absolute quantification of PVR; however, it 
also adds complexity and scanning time. Based on previous 
studies (15,16), we focused on changes in average PA 
velocity alone as an alternative method, as this was the 
parameter with the strongest correlations with PVR and the 
highest weight in the predictive model. In addition, PA 
velocity can be easily and rapidly quantified, and is more 
likely to reveal acute changes in hemodynamic conditions 
than parameters that reflect structural adaptation to chronic 
P H such as RV ejection fraction or PA dimensions. The 
presence of low PA velocities by C M R in patients with 
chronic P H has been long recognized (24,25). There are 
several mechanisms that may contribute to the tight relation 
between changes in PVR and changes in PA flow velocity. 
Increased PVR in chronic P H is associated with vasocon-
striction and remodeling of distal vessels, so blood transit 
Changes in Hemodynamic and Phase Contrast Parameters During Vasodilator Testing 
Heart rate, beats/min 
Oxygen saturation, % 
Mean BP, mm Hg 
Mean PA pressure, mm Hg 
Cardiac output, l/min 
PCWP, mm Hg 
PVR, Wood units 
PA flow velocity, cm/s 
PA minimal area, cm2 
PA elasticity, % 
Baseline 
73.5 (21.0) 
89.0 (5.0) 
85.5 (34.0) 
36.5 (14.0) 
4.7 (2.1) 
9.0 (5.0) 
4.9 (2.8) 
9.8 (2.4) 
5.8 (3.9) 
28.2 (14.0) 
Post-Vasodilator Test 
74.5 (23.0) 
98 (2.0) 
95.0 (49.7) 
27.5 (19.0) 
4.5 (2.5) 
8.2 (5.0) 
3.4 (4.1) 
11.9 (3.1) 
4.3 (3.7) 
34.2 (24.8) 
- 6 . 0 
10.0 
0.5 
- 7 . 0 
0.0 
-0 .2 
- 2 . 1 
1.5 
-1 .2 
9.7 
Change 
(-14.0 to 12.0) 
(6.0 to 18.0) 
( - 9 to 22) 
(-15.0 to -1.0) 
(-0.8 to 0.5) 
(-1 to 0) 
(-3.8 to -0.2) 
(0.4 to 4.2) 
(-1.8 to -0.6) 
( -32 to 5) 
p Value 
0.15 
<0.01 
0.61 
<0.01 
0.88 
1.00 
<0.01 
<0.01 
0.01 
0.04 
Values at baseline and post-vasodilator test are median (interquartile range) and change is expressed as median (minimum to maximum). 
Abbreviations as in Table 1 . 
Example of Pathology Changes in a Case of Post-Capillary PH and in a Case of Pre-Capillary PH 
(A) Masson'strichrome staining showing increased collagen fibers in the tunica media of the main pulmonary artery (PA). (B) Picrosirius red staining of the right ventricular (RV) 
free wall showing myocardial disarray and fibrosis (arrows). (C) Cross section of the heart showing marked RV hypertrophy and dilatation. (D) Masson's trichrome staining 
showing arterial intimal proliferation (arrows) and hypertrophy of the media (arrowheads) in the middle pulmonary lobe. (E) Masson's trichrome staining showing increased 
collagen fibers in the media of the main PA (arrow), disarray of smooth muscle cells (arrowheads), and intimal fibrosis (asterisk). (F) Masson's trichrome staining showing 
arterial medial hypertrophy and crescent-like fibrous intimal cushion (arrowheads) that causes luminal narrowing and adventitial thickening (arrows). (G) Picrosirius red staining 
of the RV free wall showing myocardial fibrosis (arrows). (H) Masson's trichrome staining showing adventitial thickening and vasculitis with transmural infiltration of 
lymphocytes (arrowheads). Obliteration, fibrosis, and recanalization of a thrombosed pulmonary artery (arrows). LV = left ventricle; PH = pulmonary hypertension. 
through the pulmonary tree is hampered. Increased PVR 
subsequently causes PA dilatation and associated changes 
of flow pattern characterized by the presence of systolic 
retrograde flow (24) and the formation of flow vortices (21) 
(as shown in Fig. 6, Online Videos 1 and 2). Finally, as P H 
progresses, the RV fails and cardiac output tends to decrease. 
The combination of all these mechanisms causes, for any 
given flow and PA pressure, a reduction in average velocity. 
In contrast with other techniques such as Doppler echo-
cardiography or catheter-tip velocity transducer, C M R 
allows for average flow velocity from the complete PA cross-
sectional area through the entire cardiac cycle avoiding the 
wrong assumption of a uniform PA flow profile. 
For the objective of monitoring changes in PVR during 
follow-up, PA velocity alone performed as well as the more 
complex method and is significantly simpler. As additional 
advantages, 2D flow imaging is easily acquired during free 
breathing, does not require contrast agent administration, 
and is easily processed with high intraobserver and inter-
observer reproducibility (16). Correlations with PVR varia-
tions were stronger in the post-capillary compared to the 
pre-capillary model, probably because the range of PVR 
changes was wider. In a prior small study of chronic P H 
patients with serial R H C and C M R performed at 2 different 
time points, it was observed that changes in PA velocities or 
dimensions differed between patients who experienced 
hemodynamic improvement during follow-up (26). Our 
present study with simultaneous hemodynamic assessment 
strengthens this observation without the limitations of per-
forming tests on different days with potential significant 
variations in PVR. Based on our results, we believe that in 
the presence of clinical stability and RV function stability (as 
can be accurately assessed by CMR), an increase or main-
tenance of average PA velocity could serve to delay or space 
R H C studies. Further studies will help to elucidate the 
precise role that C M R may play to monitor patients with 
chronic PH. 
A previous study (27) showed that PA distensibility, as 
assessed by CMR, was significantly higher in patients with 
a positive response in vasodilator testing performed within 
48 h. To our knowledge, ours is the first study of simulta-
neous C M R imaging and hemodynamic invasive assessment 
during acute vasodilator testing. Beyond the ability to detect 
serial PVR changes in chronic PH, we confirmed the 
hypothesized dynamic response of PA velocity to hemody-
namic conditions and demonstrated strong correlations 
between acute fluctuations in average PA velocity and PVR. 
Consequently, another interesting and potential application 
of noninvasive PVR monitoring with C M R could be the 
evaluation of pulmonary vascular reactivity. Our results 
suggest that vasodilator testing could be incorporated into 
the comprehensive C M R study of chronic P H patients. 
Several medications might be used as vasodilators. W e 
decided to use high oxygen dose due to its availability, easy 
administration, safety, and demonstrated effect in experi-
mental P H models (18). Moreover, oxygen has been tradi-
tionally used for vasodilator testing in pediatric patients (28), 
a population especially attractive to conduct noninvasive 
evaluation avoiding radiation and instrumentation. 
Study limitations. Some limitations of this investigation 
should be acknowledged. CMR-compatible Swan-Ganz 
catheters do not have thermistor, so the value of cardiac 
output used for the calculation of PVR during C M R in the 
acute models was not derived from thermodilution (the gold 
standard) but from phase-contrast imaging. However, 
phase-contrast is well validated and we could demonstrate an 
excellent correlation between both techniques when ther-
modilution was performed immediately before imaging and 
all conditions were steady state. W e applied the temporal 
resolution typically used in clinical evaluations as a compro-
mise between quality and acquisition time. The pre-capillary 
P H model generated by repeated pulmonary embolizations 
created only mild P H as compared with the post-capillary 
model. Although it was helpful to evaluate the behavior of 
serial cardiac M R imaging with mild changes or stability of 
PVR and to test the C M R method in 2 different models of 
chronic PH, it has to be recognized that P H severity was low 
in the pre-capillary model. Related with this issue, the range 
of PVR changes along the follow-up was narrower, which 
may explain the lower correlation between changes in PVR 
and PA velocity, as compared with the post-capillary model. 
Further studies are needed to evaluate the utility of nonin-
vasive C M R monitoring in patients with severe pre-capillary 
P H and to confirm the correlation between acute change in 
average PA velocity and acute reduction in PVR using other 
vasodilators such as nitric oxide or epoprostenol. 
Conclusions 
C M R allows noninvasive monitoring of serial changes of 
PVR in chronic P H and the acute response of PVR during 
vasodilator testing. This may be of great value in the eval-
uation and follow-up of patients with chronic PH. 
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